Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viemed HealthcareVMD -3.16%93 Return-on-Tangible-Asset is 7.48% as of Mar. 2026, which is 22% below its 10-year median of 9.54. GuruFocus rates VMD with a GF Score™ of 93/100 and a GF Value™ of $10.93 (Fairly Valued). The stock has 7 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Viemed Healthcare ranks better than 84% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Viemed Healthcare's annualizedNet Income for the quarter that ended in Mar. 2026 was $10.3 Mil. Viemed Healthcare's average total tangible assets for the quarter that ended in Mar. 2026 was $138.1 Mil. Therefore, Viemed Healthcare's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 7.48%.
The historical rank and industry rank for Viemed Healthcare's Return-on-Tangible-Asset or its related term are showing as below:
VMD'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.98 Med: 9.54 Max: 32.31
Current: 10.43
During the past 10 years, Viemed Healthcare's highest Return-on-Tangible-Asset was 32.31%. The lowest was 4.98%. And the median was 9.54%.
VMD's Return-on-Tangible-Asset is ranked better than 84% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs VMD: 10.43
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Viemed Healthcare Return-on-Tangible-Asset Related Terms
Viemed Healthcare Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Viemed Healthcare's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VMD vs DCTH, VREX, SI: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Viemed Healthcare's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viemed Healthcare Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viemed Healthcare's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Viemed Healthcare's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.48% mean?
Viemed Healthcare (VMD) has a Return-on-Tangible-Asset of 7.48% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Viemed Healthcare and its competitors. This is 22% below median its historical median of 9.54. Over the past decade, Viemed Healthcare's Return-on-Tangible-Asset has ranged from 4.98 to 32.31. According to the industry distribution chart, Viemed Healthcare ranks #137 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 16%.
Is Viemed Healthcare's Return-on-Tangible-Asset too high?
Viemed Healthcare's current Return-on-Tangible-Asset of 7.48% is 22% below median its 10-year median of 9.54. Over the past 10 years, this metric has ranged from a low of 4.98 to a high of 32.31. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Viemed Healthcare's value of 7.48% is 1157.1% above this industry median. Based on the distribution chart, Viemed Healthcare ranks #137 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Viemed Healthcare has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Viemed Healthcare's Return-on-Tangible-Asset compare to DCTH and VREX?
According to the Medical Devices & Instruments industry distribution chart, Viemed Healthcare ranks #137 out of 856 companies for Return-on-Tangible-Asset. This places Viemed Healthcare in the top 16% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.60. Viemed Healthcare's value of 7.48% is 1157.1% above this benchmark. Historically, Viemed Healthcare's own Return-on-Tangible-Asset has ranged from 4.98 to 32.31 over the past decade. While the company's 10-year median is 9.54 vs. the industry median of 0.60, Viemed Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viemed Healthcare's current Return-on-Tangible-Asset of 7.48% is 1157.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Viemed Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viemed Healthcare's current Return-on-Tangible-Asset is 7.48%, which is 22% below median its own 10-year median of 9.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viemed Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Viemed Healthcare (VMD) is currently considered Fairly Valued. The stock's GF Value™ is $10.93, compared to a current price of $11.94 — trading 9.2% above its estimated fair value. The current Return-on-Tangible-Asset is 7.48%, which is 22% below median its 10-year median of 9.54 and 1157.1% above the Medical Devices & Instruments industry median of 0.60. Viemed Healthcare's overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Viemed Healthcare (VMD), the current Return-on-Tangible-Asset is 7.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viemed Healthcare (VMD) Overvalued in 2026?
Based on GuruFocus' analysis, Viemed Healthcare stock appears to be overvalued.
The current stock price of $11.94 is trading 9.2% above its estimated GF Value™ of $10.93.
GuruFocus considers Viemed Healthcare to be Fairly Valued.
Key valuation signals for VMD:
Return-on-Tangible-Asset: 7.48% (22% below median its 10-year median of 9.54)
GF Value™: $10.93 vs. price of $11.94 (9.2% above fair value)
Industry Position: 1157.1% above the Medical Devices & Instruments median (#137 of 856)
No single metric tells the full story. See the VMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
93GF Score
Get the complete analysis for VMD
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMD has been successfully added to your 
